BTG3 and systemic lupus erythematosus: In the 2019 EULAR/ACR criteria, ANA, tested by immunofluorescence on HEp-2 cells or an equivalent solid-phase ANA screening immunoassay, was introduced as an entry criterion hereby excluding ANA negative patients to be classified as having SLE [2,5].